sulpiride has been researched along with Adenoma, Prolactin-Secreting, Pituitary in 9 studies
Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)
sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Antipsychotic drugs are the mainstay of treatment in schizophrenia." | 1.35 | Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases. ( Akkaya, C; Ersoy, C; Kaya, B; Kirli, S; Kotan, Z; Sarandol, A, 2009) |
| "Although all of 19 prolactinomas tested expressed gp130 and LIFR subunit mRNA and immunoreactive protein, only 3 of 19 prolactinomas expressed LIF mRNA." | 1.32 | Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells. ( Ben-Shlomo, A; Culler, MD; Heaney, AP; Melmed, S; Miklovsky, I; Ren, SG; Yong, WH, 2003) |
| "However, there are prolactinomas that are difficult to treat." | 1.31 | Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas. ( Castro, MG; Lowenstein, PR; Morris, ID; Smith-Arica, JR; Stone, D; Williams, JC, 2001) |
| "The most effective therapy of human prolactinomas is represented by dopamine D-2 receptor agonists; there is, however, a population of nonresponder patients who require surgical intervention." | 1.29 | Nerve growth factor suppresses the transforming phenotype of human prolactinomas. ( Balsari, A; Boroni, F; Dal Toso, R; Giovanelli, M; Losa, M; Missale, C; Spano, P; Zanellato, A, 1993) |
| "Patients with prolactinoma showed much greater TSH responses than normal subjects on the first day." | 1.28 | Evidence for dopamine-related and TRH-related pituitary TSH and PRL pools in patients with prolactinoma. ( Hanew, K; Shimizu, Y; Sugawara, A; Utsumi, A; Yoshinaga, K, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akkaya, C | 1 |
| Kaya, B | 1 |
| Kotan, Z | 1 |
| Sarandol, A | 1 |
| Ersoy, C | 1 |
| Kirli, S | 1 |
| Höfer, P | 1 |
| Friedrich, F | 1 |
| Vyssoki, B | 1 |
| Spindelegger, C | 1 |
| Schmook, M | 1 |
| Barnas, C | 1 |
| Lesch, OM | 1 |
| Walter, H | 1 |
| Ben-Shlomo, A | 1 |
| Miklovsky, I | 1 |
| Ren, SG | 1 |
| Yong, WH | 1 |
| Heaney, AP | 1 |
| Culler, MD | 1 |
| Melmed, S | 1 |
| Perroud, N | 1 |
| Huguelet, P | 1 |
| Knoepfelmacher, M | 1 |
| Villares, SM | 1 |
| Nicolau, W | 1 |
| Germek, OO | 1 |
| Lerário, AC | 1 |
| Wajchenberg, BL | 1 |
| Liberman, B | 1 |
| Missale, C | 1 |
| Boroni, F | 1 |
| Losa, M | 1 |
| Giovanelli, M | 1 |
| Zanellato, A | 1 |
| Dal Toso, R | 1 |
| Balsari, A | 1 |
| Spano, P | 1 |
| Azuma, K | 1 |
| Irahara, M | 1 |
| Aono, T | 1 |
| Williams, JC | 1 |
| Stone, D | 1 |
| Smith-Arica, JR | 1 |
| Morris, ID | 1 |
| Lowenstein, PR | 1 |
| Castro, MG | 1 |
| Hanew, K | 1 |
| Utsumi, A | 1 |
| Sugawara, A | 1 |
| Shimizu, Y | 1 |
| Yoshinaga, K | 1 |
1 review available for sulpiride and Adenoma, Prolactin-Secreting, Pituitary
| Article | Year |
|---|---|
[Metoclopramide, sulpiride, and chlorpromazine loading test].
Topics: Chlorpromazine; Humans; Hyperprolactinemia; Metoclopramide; Pituitary Function Tests; Pituitary Glan | 1997 |
8 other studies available for sulpiride and Adenoma, Prolactin-Secreting, Pituitary
| Article | Year |
|---|---|
Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases.
Topics: Adult; Amisulpride; Antipsychotic Agents; Brain; Female; Humans; Hyperprolactinemia; Magnetic Resona | 2009 |
Hyperprolactinaemia and acute psychosis: prolactinoma or medication-induced phenomenon?
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Female; Follow-Up Studies; Humans; Hyperprolacti | 2010 |
Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.
Topics: Adenoma; Animals; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Gene Expression; Growth In | 2003 |
A possible effect of amisulpride on a prolactinoma growth in a woman with borderline personality disorder.
Topics: Adult; Amisulpride; Borderline Personality Disorder; Female; Humans; Pituitary Neoplasms; Prolactin; | 2004 |
Calcium and prolactin secretion in humans: effects of the channel blocker, verapamil, in the spontaneous and drug-induced hyperprolactinemia.
Topics: Adult; Calcium; Female; Humans; Hyperprolactinemia; Male; Prolactin; Prolactinoma; Sulpiride; Thyrot | 1994 |
Nerve growth factor suppresses the transforming phenotype of human prolactinomas.
Topics: Animals; Binding, Competitive; Bromocriptine; Cell Division; Cell Membrane; Humans; Kinetics; Mice; | 1993 |
Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas.
Topics: Adenoviridae; Animals; Dopamine; Estrogens; Flow Cytometry; Gene Transfer Techniques; Genetic Therap | 2001 |
Evidence for dopamine-related and TRH-related pituitary TSH and PRL pools in patients with prolactinoma.
Topics: Adolescent; Adult; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Combinatio | 1991 |